Sea Moss for Systemic Mastocytosis: Anti-Inflammatory, Mast Cell KIT D816V & Mediator Support

Systemic mastocytosis (SM) is a clonal mast cell neoplasm caused predominantly by the KIT D816V somatic gain-of-function mutation, driving autonomous mast cell expansion in bone marrow, liver, spleen, GI tract, and skin (urticaria pigmentosa), with recurrent mediator release crises (histamine, tryptase, prostaglandin D2, heparin, leukotrienes) causing flushing, urticaria, GI symptoms, anaphylaxis, and osteoporosis. SM involves constitutive KIT/PI3K/AKT/NF-kB signaling, TSLP/SCF mast cell survival, and PGD2/LTC4/histamine vascular mediator release. Sea moss fucoidan modulates NF-kB and mast cell mediator release downstream signaling; selenium supports mast cell GPx antioxidant protection; omega-3 modulates PGD2/LTC4 mediator eicosanoids; zinc supports FOXP3+ Treg immune modulation. Midostaurin, avapritinib (KIT D816V inhibitors), cytoredution, antihistamines, and epinephrine for anaphylaxis are standard.

Read the full guide